Cargando…

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition

Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress. Yet, such cancer cells often are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic drugs....

Descripción completa

Detalles Bibliográficos
Autores principales: Kerkhofs, Martijn, Vervloessem, Tamara, Stopa, Kinga B., Smith, Victoria M., Vogler, Meike, Bultynck, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408247/
https://www.ncbi.nlm.nih.gov/pubmed/32708132
http://dx.doi.org/10.3390/biom10071081
_version_ 1783567793792221184
author Kerkhofs, Martijn
Vervloessem, Tamara
Stopa, Kinga B.
Smith, Victoria M.
Vogler, Meike
Bultynck, Geert
author_facet Kerkhofs, Martijn
Vervloessem, Tamara
Stopa, Kinga B.
Smith, Victoria M.
Vogler, Meike
Bultynck, Geert
author_sort Kerkhofs, Martijn
collection PubMed
description Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress. Yet, such cancer cells often are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic drugs. Venetoclax (ABT-199) is a selective BH3-mimetic Bcl-2 antagonist that is currently used in the clinic for treatment of chronic lymphocytic leukemia patients. Unfortunately, venetoclax resistance has already emerged in patients, limiting the therapeutic success. Here, we examined strategies to overcome venetoclax resistance. Therefore, we used two diffuse large B-cell lymphoma (DLBCL) cell lines, Riva WT and venetoclax-resistant Riva (VR). The latter was obtained by prolonged culturing in the presence of venetoclax. We report that Riva VR cells did not become more sensitive to BIRD-2, a peptide targeting the Bcl-2 BH4 domain, and established cross-resistance towards BDA-366, a putative BH4-domain antagonist of Bcl-2. However, we found that Bcl-XL, another Bcl-2-family protein, is upregulated in Riva VR, while Mcl-1 expression levels are not different in comparison with Riva WT, hinting towards an increased dependence of Riva VR cells to Bcl-XL. Indeed, Riva VR cells could be resensitized to venetoclax by A-1155463, a selective BH3 mimetic Bcl-XL inhibitor. This is underpinned by siRNA experiments, demonstrating that lowering Bcl-XL-expression levels also augmented the sensitivity of Riva VR cells to venetoclax. Overall, this work demonstrates that Bcl-XL upregulation contributes to acquired resistance of DLBCL cancer cells towards venetoclax and that antagonizing Bcl-XL can resensitize such cells towards venetoclax.
format Online
Article
Text
id pubmed-7408247
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74082472020-08-13 DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition Kerkhofs, Martijn Vervloessem, Tamara Stopa, Kinga B. Smith, Victoria M. Vogler, Meike Bultynck, Geert Biomolecules Article Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress. Yet, such cancer cells often are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic drugs. Venetoclax (ABT-199) is a selective BH3-mimetic Bcl-2 antagonist that is currently used in the clinic for treatment of chronic lymphocytic leukemia patients. Unfortunately, venetoclax resistance has already emerged in patients, limiting the therapeutic success. Here, we examined strategies to overcome venetoclax resistance. Therefore, we used two diffuse large B-cell lymphoma (DLBCL) cell lines, Riva WT and venetoclax-resistant Riva (VR). The latter was obtained by prolonged culturing in the presence of venetoclax. We report that Riva VR cells did not become more sensitive to BIRD-2, a peptide targeting the Bcl-2 BH4 domain, and established cross-resistance towards BDA-366, a putative BH4-domain antagonist of Bcl-2. However, we found that Bcl-XL, another Bcl-2-family protein, is upregulated in Riva VR, while Mcl-1 expression levels are not different in comparison with Riva WT, hinting towards an increased dependence of Riva VR cells to Bcl-XL. Indeed, Riva VR cells could be resensitized to venetoclax by A-1155463, a selective BH3 mimetic Bcl-XL inhibitor. This is underpinned by siRNA experiments, demonstrating that lowering Bcl-XL-expression levels also augmented the sensitivity of Riva VR cells to venetoclax. Overall, this work demonstrates that Bcl-XL upregulation contributes to acquired resistance of DLBCL cancer cells towards venetoclax and that antagonizing Bcl-XL can resensitize such cells towards venetoclax. MDPI 2020-07-21 /pmc/articles/PMC7408247/ /pubmed/32708132 http://dx.doi.org/10.3390/biom10071081 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kerkhofs, Martijn
Vervloessem, Tamara
Stopa, Kinga B.
Smith, Victoria M.
Vogler, Meike
Bultynck, Geert
DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title_full DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title_fullStr DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title_full_unstemmed DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title_short DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
title_sort dlbcl cells with acquired resistance to venetoclax are not sensitized to bird-2 but can be resensitized to venetoclax through bcl-xl inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408247/
https://www.ncbi.nlm.nih.gov/pubmed/32708132
http://dx.doi.org/10.3390/biom10071081
work_keys_str_mv AT kerkhofsmartijn dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition
AT vervloessemtamara dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition
AT stopakingab dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition
AT smithvictoriam dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition
AT voglermeike dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition
AT bultynckgeert dlbclcellswithacquiredresistancetovenetoclaxarenotsensitizedtobird2butcanberesensitizedtovenetoclaxthroughbclxlinhibition